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Abstract: Since the discovery of RNA interference (RNAi), excitement has grown over its
potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change
biological processes post-transcriptionally in various health conditions such as cancer or
autoimmune diseases. Optimum design of shRNA, siRNA, and miRNA enhances stability
and specificity of RNAi-based approaches whereas it has to reduce or prevent undesirable
immune responses or off-target effects. Recent advances in understanding pathogenesis of
autoimmune diseases have allowed application of these tools in vitro as well as in vivo with
some degree of success. Further research on the design and delivery of effectors of RNAi
pathway and underlying molecular basis of RNAi would warrant practical use of RNAi-based
therapeutics in human applications. This review will focus on the approaches used for
current therapeutics and their applications in autoimmune diseases, including rheumatoid
arthritis and Sjögren’s syndrome.
Keywords: RNA interference; therapeutics; microRNA; small interfering RNA;
autoimmune disease

1. Introduction
RNA interference (RNAi) is a cellular mechanism occurring in most eukaryotic cells that is
responsible for post-transcriptional gene regulation. This process involves small single stranded RNA
molecules binding to the 3' UTR of specific mRNA targets resulting in the degradation or translational
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repression of that target. Since the discovery of the RNAi pathway, there has been a focused interest on
the development of RNAi-based therapeutics for otherwise “undruggable” targets. This review will
outline the mechanism of RNAi and approaches to RNAi-based therapeutic strategies and address the
progress of RNAi-therapeutics for autoimmune diseases.
The Effectors of RNA Interference
The effectors of the RNAi pathway are small RNA (RNA) molecules that can be classified into at
least three categories based on their origin and function: microRNAs (miRNA), short interfering RNAs
(siRNA), and short hairpin RNAs (shRNA).
MiRNAs represent endogenously encoded small RNAs, about 22 nucleotides long, which function
to post-transcriptionally repress gene expression by binding to target mRNAs in a sequence specific
manner. Though discovered relatively recently, miRNA are now recognized as key regulators of gene
expression in plants and animals. The genes encoding miRNAs are transcribed by RNA polymerase II
in a long primary miRNA that is cleaved in the nucleus by Drosha/DGCR8 into a precursor miRNA
(pre-miRNA). The pre-miRNA consists of about 70 base pairs with a single-stranded hairpin loop.
Pre-miRNA is exported from the nucleus via exportin-5, and is cleaved by Dicer in the cytoplasm to
generate a mature miRNA about 22 nucleotides long. This mature miRNA is incorporated into a
complex known as the RNA-induced silencing complex (RISC) where it binds to its target mRNA
though complementary base pairing. If complementarity is perfect, mRNA degradation typically
occurs, whereas if complementarity is partial, translational repression typically occurs [1].
The shRNAs are dsRNAs engineered with a similar structure as miRNA, and are either tranfected
into cells directly or a vector encoding the shRNA is introduced into the cells and transcribed.
SiRNA molecules are synthetic dsRNAs ranging in size from about 19–30 nucleotides that function
to cause mRNA degradation through the perfect pairing of complementary sequences [2]. These
molecules have become invaluable research tools to study the functions of genes and an alternative to
knock-out mice.
2. Approaches to RNAi Therapeutics
2.1. Short Hairpin RNAs
One advantage of using shRNAs is that they assimilate into the endogenous RNAi pathway, and are
therefore more efficient than exogenously introduced siRNAs [3]. Using a viral vector-based delivery
system for shRNAs increases transfection efficiency and allows harder-to-transfect cells such as
non-dividing neuronal cells to be targeted. However, there are obvious safety concerns associated with
the use of viral expression vectors in humans. Other delivery strategies for shRNA include coupling
with monoclonal antibodies, peptides, or aptamers that recognize specific cell surface molecules, but
each of these strategies are associated with increased toxicity [4–7].
2.2. MicroRNAs
In recent years, differential expression of miRNA has been associated with a wide variety of human
diseases ranging from many types of cancer to autoimmune diseases and everything in between. This
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revelation makes them an attractive target for therapies. The premise is that if we can elucidate reliable
techniques to alter miRNA levels in specific cells/tissues, perhaps we can ameliorate disease
symptoms or cure diseases altogether. There are two main strategies that can be employed to do this.
The first is the use of synthetic miRNA mimics to restore the expression level of a particular miRNA
back to normal levels [8]. This strategy presents many of the same challenges faced by siRNA
therapies to be discussed later, such as stability and delivery. In addition, most miRNAs are pleiotropic
hence altering levels of any given miRNA may result in unintended consequences. The second strategy
is the use of miRNA “sponges” to block the action of over-expressed miRNAs [8]. Again, many of the
same challenges apply to the use of sponges including design, delivery, and the pleiotropic nature of
most miRNAs.
2.3. Small Interfering RNAs
2.3.1. Design
The main focus of this review will be on the use of siRNA molecules as therapeutic agents. When
considering the use of siRNA for therapeutic purposes, the first step is selection of an appropriately
designed siRNA that takes into account potency, specificity and stability. Algorithms have been
developed to assist in designing potent siRNA based on the target gene of interest, but once
synthesized, these siRNAs must be experimentally evaluated to determine their efficacy in gene
silencing. Specificity is another critical factor to consider. Although it has been demonstrated that
siRNAs can have selective silencing of genes that differ by a single nucleotide in sequence [9],
siRNAs can have “off-target” effects where expression of homologous mRNAs is altered or unrelated
genes are altered [10]. Furthermore, siRNAs may induce the innate immune response by activating
Toll-like receptors such as TLR7 that recognizes viral dsRNA. This could lead to a potentially harmful
inflammatory response in patients.
2.3.2. Stability
When considering the use of siRNA molecules in in vivo models, stability of the molecule becomes
another critical factor. Unprotected siRNA molecules are highly unstable and easily degraded in
human plasma, with a half-life of only five minutes [11,12]. Chemical modifications are necessary to
extend the half-life of siRNA in vivo without altering efficacy of gene silencing. Such chemical
modifications include alterations in the phosphate groups linking nucleotides that confer exonuclease
resistance or alterations (typically methylation) in the sugar residues that confer endonuclease
resistance. The right balance between increased stability and maintained efficacy must be
experimentally determined for siRNA molecules.
2.3.3. Delivery
Delivery of siRNA molecules to target cells/tissues is perhaps the most challenging factor of RNAi
therapeutics. Due to its negative charge, siRNA molecules do not penetrate cell membranes easily.
Only a few anatomically isolated sites have been shown to exhibit gene silencing after uptake of naked
siRNA. This opens up the possibility for siRNA use in these areas (eyes, lungs, central nervous
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system), but for more systemic use, delivery strategies must be developed. siRNA delivery can be
achieved by a variety of strategies including lipid-based formulations [13], nanoparticles [14], and
magnetofection [15]. However, these strategies are nonspecific, and cell-type specific delivery is still
the most challenging step blocking the progress of RNAi therapy in modern medicine. In order to
target siRNA to specific cell or tissue types, specificity must be built into the delivery agents or
expressed shRNAs. Some strategies for cell-type specific delivery include antibody targeting [16],
cell-penetrating peptides [17], chemical modifications[13], and aptamers [7], but each of these
strategies presents certain drawbacks such as cytotoxicity or immunogenicity.
Recently, Lima et al. demonstrated that single-stranded siRNA molecules are capable of
functioning through the RNAi pathway in animals and result in potent gene silencing [18]. This
finding is significant, because single-stranded siRNAs offer several advantages over dsRNAs. The lack
of a second “passenger” strand reduces the risk for off-target effects, increasing specificity of the
siRNA. More importantly, ssRNAs are easily delivered in vivo without any lipid-based transfection
reagents or other delivery vectors. Chemically modified, naked single-stranded siRNAs can be
delivered in vivo using a simple saline solution and result in potent gene silencing. This strategy may
prove very useful for a systemic therapeutic approach using siRNA. However, in many diseases,
specific cell-types or tissues must be targeted, thus a more specific delivery method must be developed.
3. RNAi Therapeutics for Autoimmune Diseases
The discovery of RNAi as a sequence-specific mechanism of gene regulation has made it an
attractive concept for the development of new therapies. Numerous clinical trials for RNAi
therapeutics have been completed or are ongoing for various diseases such as age-related macular
degeneration (AMD), glaucoma, respiratory syncytial virus (RSV), asthma, liver cancer, and pancreatic
cancer (clinical trials.gov). This review will focus on the progress of RNAi therapeutic development in
autoimmune diseases.
3.1. In Vitro Studies
One study set out to develop a siRNA-based therapeutic targeting Sjögren’s syndrome (SjS), an
autoimmune disease characterized by lymphocytic infiltration in the salivary and lacrimal glands
resulting is severe dry mouth and dry eye symptoms due in part to apoptotic cell death of secretory
acinar cells in the glands [19]. Currently, the only course of treatment available to SjS patients is
immunosuppressive therapy and secretagogues, a class of drugs that stimulate secretion. Pauley et al.
designed a conjugate composed of a siRNA molecule targeting caspase-3 and a muscarinic receptor
agonist, carbachol [19]. Carbachol binds to muscarinic receptors inducing secretion and is endocytosed
via receptor-mediated endocytosis. Linking a siRNA molecule to carbachol allows cellular uptake of
the siRNA through this receptor-mediated endocytic pathway and specific delivery of the siRNA since
only cells expressing muscarinic receptors including salivary acinar cells would be targeted. Pauley et al.
showed that both the siRNA and carbachol remained functional after conjugation and HSG cells
treated with conjugate (in the absence of transfection reagent) exhibited significant reduction in
caspase-3 gene/protein expression, indicating that the conjugate is taken up by cells via muscarinic
receptor-endocytosis. More importantly, inflammatory cytokine-induced apoptosis of HSG cells was
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inhibited by conjugate treatment [19]. These data suggest that this strategy may be useful to prevent
apoptotic cell death of secretory acinar cells in SjS patients, thus maintaining secretory function to
improve quality of life for the patients. Further studies are needed to continue developing this
conjugate for in vivo use.
3.2. In Vivo Studies
Several studies have examined the potential use of siRNA therapy in rheumatoid arthritis (RA).
In 2005, Schiffelers et al. investigated the use of localized electroporation for in vivo delivery of
siRNA into joint tissue of arthritic mice [20]. It was demonstrated that electroporation of anti-TNFα
siRNA resulted in inhibition of joint inflammation in collagen-induced arthritis. A later study by
Khoury et al. in 2006 utilized a DNA molecule for complexation and a cationic liposome for the
intravenous delivery of anti-TNFα siRNA in collagen-induced arthritic mice [21]. When administered
weekly, a 50%–70% reduction of TNF-α and an almost complete ablation of arthritic symptoms was
observed in siRNA-treated mice. However, this systemic delivery approach resulted in uptake of
siRNA by multiple organs including brain, lungs, liver and spleen.
A more recent study extended this work by testing the efficacy of a “wraposome” to systemically
deliver siRNA to arthritic joints in collagen-induced arthritic mice [22]. A wraposome consists of a
core composed of a cationic lipid bilayer and siRNA complex enveloped in a neutrak lipid bilayer with
polyethylene glycol on the surface. This design results in a neutral surface charge and prevents the
non-specific binding of the liposome to plasma proteins after intravenous injection. Collagen-induced
arthritic mice receiving siRNA targeting TNF-α via this systemic wraposome delivery exhibited
significant decreases in the severity of arthritis coupled with reduction of TNF-α in the joints.
Interestingly, the siRNA was mainly incorporated into macrophages and neutrophils in the inflamed
synovium [22]. These findings support the potential therapeutic effects of suppressing inflammatory
molecules via siRNA in rheumatoid arthritis.
Yet another study examining the potential use of RNAi therapy in an arthritis animal model used a
different strategy. Chen et al. used a lenti-viral vector to deliver short hairpin RNA targeting TLR7 in
collagen-induced arthritic mice [23]. Again, severity of arthritis symptoms and expression of
inflammatory mediators in the joints were reduced in treated mice compared to untreated mice.
In addition to siRNA therapeutic potential in RA, certain miRNAs, particularly miR-146a, have
been found to be differentially expressed in RA and other autoimmune diseases such as Sjögren's
syndrome and systemic lupus erythematosus (SLE) [24–32]. One study demonstrated the potential
therapeutic application of miR-146a for RA by demonstrating the inhibitory effect of miR-146a on
osteoclastogenesis in vitro [33]. Furthermore, Nakasa et al. were able to demonstrate that intravenous
administration of miR-146a resulted in the suppression of cartilage and bone destruction in a collagen-induced
arthritis mouse model [33]. These findings support the therapeutic potential of miRNA modulation in
autoimmune diseases. However, further studies are needed to identify and understand differentially
expressed miRNAs in autoimmune disease patients.
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4. Conclusions
Despite significant progress in the field of RNAi therapeutics, there is still much research needed to
perfect the design and delivery of siRNA in humans. Although several clinical trials using RNAi
therapeutics have been completed, new problems have surfaced including unintended immunological
effects, effects on the endogenous RNA silencing pathway, and the ultimate dilemma of how to
effectively deliver siRNA in vivo. Regardless of these setbacks, hope still remains that with time,
RNAi therapeutics will prove to be the next “superdrug” against a variety of human diseases.
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